INTRODUCTION
============

Kidney organoids are generated from human pluripotent stem cells (hPSCs) *in vitro* \[[@b1-kjim-2018-198]-[@b4-kjim-2018-198]\]. Kidney organoids derived from hPSCs contain nephrogenic progenitor cells of multiple lineages that can recapitulate kidney development \[[@b5-kjim-2018-198]\]. A direct comparison of gene expression and localization between kidney organoids *in vitro* and human kidneys revealed that podocytes derived from hPSCs resemble podocytes *in vivo* at the capillary loop stage (CLS) of glomerular development \[[@b5-kjim-2018-198]\]. Several review articles describing differentiation of kidney organoids from hPSCs have been published. Here, we focus on the applications of kidney organoids derived from hPSCs.

APPLICATIONS OF KIDNEY ORGANOIDS DERIVED FROM HUMAN hPSCs
=========================================================

Kidney organoids derived from hPSCs have potential applications in regenerative medicine, as well as in the modeling of renal diseases, drug screening, and nephrotoxicity testing of compounds. Although more research is needed to improve differentiation protocols and obtain fully functional kidney organoids, clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR-associated system 9 (Cas9) genome editing and three-dimensional (3D) bioprinting have facilitated realization of functional kidney organoids and their applications in clinical fields. In this section, we review recent advances in the applications of kidney organoids in kidney disease modelling, drug screening, nephrotoxicity testing, and regenerative therapy ([Fig. 1](#f1-kjim-2018-198){ref-type="fig"}).

DISEASE MODELING
================

Kidney disease modeling using kidney organoids derived from hPSCs has revealed novel mechanisms of kidney diseases and allows drug screening to develop new therapies. Advanced technologies for differentiating kidney organoids from hPSCs, as well as efficient genome editing systems, such as the CRISPR-Cas9 system, have enabled researchers to model human kidney diseases.

One of the most important issues in this field is the modeling of renal diseases with a genetic basis. Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disease, and is present in approximately 5% of patients with total end-stage renal disease (ESRD). Numerous fluid-filled cysts form and grow in both kidneys, accompanied by interstitial fibrosis, resulting in chronic kidney disease (CKD) in 50% of patients by the age of 60 years \[[@b6-kjim-2018-198]\]. ADPKD is associated with mutations in the *PKD1* and *PKD2* genes \[[@b6-kjim-2018-198]\], which encode polycystin-1 and polycystin-2, respectively \[[@b6-kjim-2018-198],[@b7-kjim-2018-198]\]. The mechanism for the development of ADPKD remains unclear and treatment options for ADPKD are limited.

Freedman's research group modeled PKD using kidney organoids derived from hPSCs \[[@b8-kjim-2018-198],[@b9-kjim-2018-198]\]. They produced hPSCs with loss-of-function mutations in either *PKD1* or *PKD2* using CRISPR-Cas9 genome editing and differentiated these mutant hPSCs into kidney organoids. CRISPR-mutant *PKD1* and *PKD2* knockout kidney organoids (PKD organoids) had cysts in the kidney tubules, phenocopying ADPKD.

PKD organoids derived from hPSCs have major advantages over currently available kidney disease models, such as *PKD1* or *PKD2* mutant mouse or renal cells from patients with ADPKD \[[@b8-kjim-2018-198]-[@b11-kjim-2018-198]\]. Although *PKD1* and *PKD2* mouse mutants have provided valuable insight into disease mechanisms, the survival time of *PKD1* and *PKD2* knockout mice is very short, and *PKD1* and *PKD2* heterozygotes have only very mild cystic disease, unlike human ADPKD \[[@b12-kjim-2018-198]\]. Therefore, PKD organoids derived from hPSCs may be a better model of human ADPKD. In addition, PKD organoids are more accessible than animal models and their use does not require ethical approval. Cultures of renal cells from patients with ADPKD can also be used to model ADPKD *in vitro* \[[@b13-kjim-2018-198]\]. However, this system suffers from heterogeneities in the cell sources and the epigenetic background of each patient; thus, the results need to be interpreted with caution \[[@b11-kjim-2018-198],[@b13-kjim-2018-198]\]. In contrast, CRISPR-mutant PKD organoids derived from hPSCs have isogenic negative controls, which allows causality to be more clearly established when investigating disease mechanisms \[[@b8-kjim-2018-198],[@b9-kjim-2018-198],[@b14-kjim-2018-198]\].

PKD organoids can not only be used to recapitulate the phenotypic characteristics of ADPKD, but also to investigate the mechanisms of ADPKD cystogenesis \[[@b8-kjim-2018-198]\]. Freedman and colleagues \[[@b8-kjim-2018-198]\] established a highly efficient culture system for PKD organoids to model PKD cystogenesis. They cultured PKD organoids in low-attachment plates instead of in the previous adherent culture system, which resulted in the formation of larger cysts phenotypically resembling PKD \[[@b8-kjim-2018-198]\]. In this culture system, the cystogenesis rate of the PKD mutant organoids was much higher than that of isogenic control organoids. Using this system, the role of the extracellular matrix (ECM) microenvironment in the cystogenesis of PKD was investigated \[[@b8-kjim-2018-198]\]. The authors provided direct evidence for the role of the ECM microenvironment in cystogenesis in PKD, by embedding the PKD organoids into collagen droplets. Embedding the *PKD1* mutant organoids into collagen droplets dramatically decreases cyst formation, but removing the adherent cues abolished the ability of collagen droplets to reduce cyst size \[[@b8-kjim-2018-198]\]. The authors also reported that the size of organoids increased, and cystogenesis was promoted, when cyclic adenosine monophosphate (cAMP) was added \[[@b8-kjim-2018-198]\]. These approaches provide valuable insight into the underlying mechanisms of ADPKD and could aid in the development of therapeutics.

Mutations in vital genes in podocytes may cause podocytopathies, such as focal segmental glomerulosclerosis (FSGS), which is one of the leading glomerular-related causes of ESRD and has diverse genetic origins \[[@b15-kjim-2018-198],[@b16-kjim-2018-198]\]. Podocalyxin (*PODXL*) is highly localized on the apical and lateral surfaces of podocytes and may be a candidate gene for FSGS \[[@b17-kjim-2018-198]\]. Kim et al. \[[@b5-kjim-2018-198]\] demonstrated the functional role of *PODXL* in the development of podocyte disease using kidney organoids. They generated gene-edited *PODXL*^--/--^ hPSCs and isogenic controls using the CRISPR-Cas9 system and differentiated these hPCSs to form kidney organoids. *PODXL*^--/--^ hPSC-podocytes had defects in basal junctional migration. *PODXL*^--/--^ hPSC-podocytes also failed to assemble microvilli, with the absence of microvilli being accompanied by a reduction in lateral spaces between adjacent podocytes \[[@b5-kjim-2018-198]\]. Importantly, these findings in *PODXL*^--/--^hPSC-podocytes were validated in the CLS glomeruli of *PODXL*-deficient mice \[[@b5-kjim-2018-198]\]. Furthermore, human patients with biallelic loss-of-function mutations in *PODXL* may have congenital nephrotic syndrome \[[@b17-kjim-2018-198]\]. That study demonstrated the potential usefulness of kidney organoids derived from hPSCs to model podocyte diseases.

There are at least 150 different genetic renal disorders worldwide and nearly all children with a genetic renal disorder progress to ESRD \[[@b18-kjim-2018-198]\]. Kidney organoid systems combined with CRISPR genome editing can aid in the modeling of genetic renal disorders, which is likely to provide valuable insight facilitating the development of new therapies.

DRUG SCREENING AND NEPHROTOXICITY TESTING
=========================================

Renal tubular cell-based approaches
-----------------------------------

Most newly developed drugs have nephrotoxic potential, and predicting nephrotoxicity during preclinical drug development is essential \[[@b19-kjim-2018-198]\]. Several cell types have been used for *in vitro* nephrotoxicity assays, and each cell type has advantages and disadvantages ([Table 1](#t1-kjim-2018-198){ref-type="table"}) \[[@b19-kjim-2018-198],[@b20-kjim-2018-198]\]. Madin-Darby canine kidney cells, which are a well-established cell line, form a polarized tight monolayer, but show differences from those in humans and are poor predictors of nephrotoxicity \[[@b20-kjim-2018-198]\].

Proximal tubular (PT) cells have numerous active transporters to reabsorb filtered drug metabolites, resulting in a high intracellular accumulation of drug metabolites \[[@b19-kjim-2018-198]-[@b22-kjim-2018-198]\]. Thus, nephrotoxic drugs are likely to affect PT cells \[[@b20-kjim-2018-198]\]. For this reason, PT cells have been widely used to develop *in vitro* platforms for drug screening or nephrotoxicity testing \[[@b20-kjim-2018-198]\]. Proximal-like porcine kidney 1 (LLC-PK1) cells (porcine PT cell line), human kidney 2 (HK-2) cells (immortalized human PT cell line), and primary renal PT epithelial cells from different donors are widely used as cell sources for PT cells. *In vitro* platforms using PT cells have been reported; their sensitivity and accuracy are within the range of 70% to 90% depending on the PT cell type \[[@b19-kjim-2018-198],[@b23-kjim-2018-198],[@b24-kjim-2018-198]\]. However, HK-2 cells have few transporters or proximal tubule characteristics \[[@b25-kjim-2018-198],[@b26-kjim-2018-198]\] and show a tendency to lose their transepithelial transport function once they undergo the epithelial-to-mesenchymal transition \[[@b27-kjim-2018-198]\]. Primary human renal PT epithelial cells have transepithelial transporters and express metabolic enzymes, and are also available for a broad range of biomarker assays. This cell line is suitable for nephrotoxicity testing and show high predictivity \[[@b20-kjim-2018-198],[@b28-kjim-2018-198],[@b29-kjim-2018-198]\]. However, these cells rapidly lose their PT characteristics during prolonged culture, and there is donor-to-donor variability and possible contamination with other renal cell types when the cells are isolated from donors due to heterogeneity of the kidney \[[@b20-kjim-2018-198],[@b30-kjim-2018-198]\].

hPSC-based approaches
---------------------

Differentiating hPSCs into PT epithelial cell-like cells is an alternative and attractive approach to establish an *in vitro* model. One research group reported an accuracy of 76% for an *in vitro* model based on embryonic stem cell-derived human renal PT-like cells \[[@b31-kjim-2018-198]\]. However, embryonic stem cell-derived human renal PT-like cells have not been sufficiently characterized \[[@b32-kjim-2018-198]\] and their use is not free from ethical and legal issues.

Thus, human inducible pluripotent stem cell (iPSC)-based models are alternative and attractive *in vitro* models. A protocol to differentiate human iPSCs into PT-like cells and establish a human iPSC-based model for predicting nephrotoxicity has been published \[[@b33-kjim-2018-198]\]. Using this protocol, PT-like cells with a purity \> 90% were obtained from iPSCs. This human iPSC-based model was used to predict the toxicity of 30 compounds to PT cells; the training accuracy of the model was 99.8%, and the test accuracy was 87.0% \[[@b33-kjim-2018-198]\]. Although the model can predict nephrotoxicity with reasonable accurately, it does not mimic the diversity of cells, ECM, or vascularization associated with actual human kidneys. Thus, a human iPSC-based model is required to extrapolate *in vitro* evidence to the *in vivo* environment \[[@b20-kjim-2018-198]\].

Kidney organoids derived using hPSC-based approaches
----------------------------------------------------

Cell-to-cell and cell-to-ECM interactions control cell phenotypes and functions *in vivo* \[[@b34-kjim-2018-198]-[@b36-kjim-2018-198]\]. Maintaining these interactions is required to maintain tissue-like responses in an *in vitro* model in the context of drug efficacy and toxicity screening \[[@b37-kjim-2018-198]\]. Two-dimensional cultures on culture plastic using a single renal cell type may have difficulty in recapitulating these complex conditions. In contrast to conventional kidney cell lines or iPSC-derived PT cells, individual kidney organoids have all of the major components of developing proximal nephrons, namely tubular cells, endothelial cells, nephron progenitors, and podocyte-like cells \[[@b1-kjim-2018-198],[@b4-kjim-2018-198],[@b9-kjim-2018-198]\], and are therefore promising systems for drug screening and nephrotoxicity testing.

Some research groups have tested the nephrotoxicity of gentamycin or cisplatin on kidney organoids derived from hPSCs \[[@b1-kjim-2018-198],[@b4-kjim-2018-198],[@b9-kjim-2018-198]\]. After kidney organoids were treated with gentamycin or cisplatin, increased expression of kidney injury molecule-1, a clinical biomarker of acute kidney injury (AKI) \[[@b1-kjim-2018-198],[@b9-kjim-2018-198]\], or cleaved caspase 3, a marker of apoptosis \[[@b4-kjim-2018-198]\], was observed by immunofluorescence staining or real-time quantitative polymerase chain reaction. These data support the use of kidney organoids as a platform for nephrotoxicity testing. However, more nephrotoxic drugs and non-nephrotoxic compounds have to be evaluated before kidney organoids can be used as a drug testing platform, and the results must be compared with tubular cell-based models or hPSC-based models.

HIGH-THROUGHPUT APPLICATIONS
============================

Accurate high-throughput methods to screen large numbers of compounds are essential to reduce time and cost during drug development \[[@b38-kjim-2018-198]\]. Some groups have developed a predictive screening platform with high efficiency and accuracy by combining cell-based (HK-2 cells and human primary renal PT cells) and computational methods \[[@b38-kjim-2018-198],[@b39-kjim-2018-198]\].

Kidney organoids derived from hPSCs have great potential in high-throughput screening because of their specificity to humans and ability to model complex kidney disease phenotypes \[[@b40-kjim-2018-198]\]. However, the complexity of kidney organoid cultures has been a significant obstacle to miniaturization and automation \[[@b40-kjim-2018-198]\]. Czerniecki et al. \[[@b40-kjim-2018-198]\] established a fully automated, high-throughput screening-compatible system using liquid-handling robots and a 21-day organoid culture protocol, from plating to analysis via differentiation. They demonstrated that this high-throughput screening system improved differentiation of kidney organoids. Using this system, they modeled nephrotoxicity and disease phenotypes and quantified the system in terms of its safety and prediction efficacy. They also applied the system to drug screening. They cultured PKD mutant organoids in 96-well plates treated with different compounds and demonstrated that blebbistatin, a specific inhibitor of non-muscle myosin II, induces a significant increase in cyst formation, which revealed an unexpected role for myosin in polycystic kidney disease \[[@b40-kjim-2018-198]\].

Although limitations, for example in terms of the immaturity or functionality of kidney organoids derived from hPSCs still remain, high-throughput systems based on kidney organoids derived from hPSCs may be a valuable tool for new drug development or nephrotoxicity testing.

APPLICATIONS WITH 3D BIOPRINTING
================================

Another important application of kidney organoids is 3D bioprinting. Three-dimensional bioprinting enables layer-by-layer precise positioning of biological and biochemical materials, and living cells, with spatial control of the placement of functional components to fabricate complex 3D living tissues or organs \[[@b41-kjim-2018-198]\]. Three-dimensional bioprinting has advantages over non-biological printing because 3D bioprinting can be used to fabricate complex structures, by choosing different materials, cell types, and growth and differentiation factors. Three-dimensional bioprinting provide opportunities to meet technical challenges related to the sensitivity of living cells and the tissue construction \[[@b41-kjim-2018-198]\]. Thus, application of 3D bioprinting technologies to regenerative medicine is an important issue.

Three-dimensional bioprinting can be applied in two ways to regenerative medicine for kidney diseases. Drug screening using a drug library is important during new drug development, and nephrotoxicity testing should be performed before clinical use of a newly developed compound. For drug screening or nephrotoxicity testing, 3D bioprinting can generate biologically mini kidney tissues, the so-called "kidney on a chip."

One research group has developed a bioprinting method for printing 3D convoluted renal proximal tubules embedded in ECM *in vitro* on customized perfusion chips with a microfluidic network, by precisely co-printing bioink with multiple materials \[[@b42-kjim-2018-198]\]. Using this system, kidney tissue-like epithelium with phenotypic and functional properties similar to those of real kidney tissue can be obtained. For this chip to be used in drug screening applications, the presence of appropriate vasculature may be essential to reproduce organ-scale drug delivery pharmacokinetics, because vasculature is important when mimicking organ-level functions in micro-tissues \[[@b43-kjim-2018-198]\]. Perfusable 3D proximal tubules promote the formation of a tissue-like epithelium with improved phenotypic and functional properties and mimic blood flow in vascular channels. Although no nephrogenic progenitor cells are used in this system, it could facilitate drug screening and mechanistic drug studies.

Organovo Inc. (San Diego, CA, USA) recently generated 3D bioprinted kidney tissue for compound screening and disease modelling \[[@b44-kjim-2018-198]\]. They optimized a method to form a polarized layer of renal epithelium on top of the interstitial layer, and a basement membrane between the layers; this tissue may provide insight into the effects of cell-cell interactions on the nephrotoxicity of a compound \[[@b44-kjim-2018-198]\].

Because kidney organoids are composed of diverse renal cells, including podocytes, tubular cells, endothelial cells, and stromal cells, and form nephron-like structures with functionality, they are suitable biomaterials for 3D bioprinting to produce efficient kidneys on a chip. Several research groups are trying to develop new methods to realize kidney tissues on a chip using kidney organoids derived from hPSCs.

Another application of 3D bioprinting of kidney organoids is generating organotypic scaffolds for transplantable bioengineered kidneys. One research group generated bioengineered bladders by 3D bioprinting and transplanted them into seven patients with non-functional bladders \[[@b45-kjim-2018-198]\]. They generated a biodegradable scaffold and seeded urothelial and muscle cells into the bioengineered bladder scaffolds \[[@b45-kjim-2018-198]\]. However, unlike the bladder, vessels, or trachea bioengineered by 3D bioprinting \[[@b46-kjim-2018-198]\], the kidney contains 1 million nephrons consisting of diverse cells with different functions and origins. Given the complex structure and functional nature of the kidney, and the absence of an organized urinary excretion system in kidney organoids, bioprinted functional kidney tissues have not been realized despite advances in bioprinting technologies \[[@b47-kjim-2018-198]\].

REGENERATIVE THERAPY USING KIDNEY ORGANOIDS
===========================================

The incidence and prevalence of CKD is increasing in developed countries, leading to ESRD requiring renal replacement therapy, such as dialysis or kidney transplantation \[[@b48-kjim-2018-198]\]. However, dialysis is limited by high mortality, and kidney transplantation is limited by the shortage of donor organs \[[@b49-kjim-2018-198]-[@b53-kjim-2018-198]\]. Therefore, new therapeutic options are urgently needed. Regenerative medicine, in which the nephrons lost during the progression of CKD are replaced by stem cells, is a potentially attractive therapeutic option for CKD. In this section, we review the possible regenerative medicine options afforded by kidney organoids.

Transplantation and cell therapy using kidney organoids
-------------------------------------------------------

Kidney organoids have multi-lineage nephrogenic progenitor cells, and immunosuppression is not needed to transplant kidney organoids derived from patients. Thus, transplanting kidney organoids is an attractive regenerative therapy. However, this may not be achievable in a short time frame, for several reasons. The evidence of functionality of kidney organoids remains insufficient. It is not easy to generate the urine collecting system and connect it with the host urinary system. The safety of iPSCs and the immune barrier in ESCs also limit transplantation of kidney organoids derived from hPSCs \[[@b10-kjim-2018-198]\].

Nevertheless, some researchers have reported encouraging data \[[@b2-kjim-2018-198],[@b54-kjim-2018-198]-[@b57-kjim-2018-198]\]. Taguchi et al. \[[@b2-kjim-2018-198]\] generated metanephric nephron progenitor from mouse ESCs and transplanted them beneath the kidney capsule of immunodeficient mice. Tubulogenesis and formation of glomerular-like structures were observed in the transplanted graft. The transplanted glomeruli vascularized with the host circulation and contained red blood cells.

Another study also reported encouraging data. Sharmin et al. \[[@b55-kjim-2018-198]\] generated human iPSC cell lines expressing green fluorescent protein in the NPHS1 locus using transcription activator-like effector nuclease-mediated homologous recombination, and then induced 3D primordial glomeruli from these iPSCs. They reported that the induced human podocytes derived from iPSCs exhibited apicobasal polarity, by showing the location of an in-basal domain with primary foot process-like structures that were connected with slit diaphragm-like structures. They developed a transplantation technique to effectively form glomeruli from human iPSC-derived nephron progenitors using spacers that released tension from the host kidney capsules. Using this technique, induced glomeruli were transplanted from human iPSCs into the mouse kidney subcapsular space, followed by treatment with vascular endothelial growth factor (VEGF) \[[@b55-kjim-2018-198]\]. The transplanted human glomeruli were vascularized with the host mouse endothelial cells, and the iPSC-derived podocytes had numerous cell processes that accumulated around the fenestrated endothelial cells, forming slit diaphragm-like structures.

Another study reported functional vascularization with progressive morphogenesis of human kidney organoids after renal subscapular transplantation. van den Berg et al. \[[@b57-kjim-2018-198]\] transplanted kidney organoids derived from hPSCs into mouse kidney subcapsular spaces and reported that the transplanted hPSC-derived kidney organoids develop host-derived vascularization in the absence of any exogenous VEGF. They also showed functional glomerular perfusion with connection to host mouse vascular networks by *in vivo* imaging of the transplanted kidney organoids under the mouse kidney capsule. They revealed that transplantation induced the formation of a slit diaphragm structure consisting of the glomerular basement membrane, fenestrated endothelial cells, and podocyte foot processes in an ultrastructural analysis. They also observed specialized (i.e., more polarized and segmented) tubular epithelium in transplanted kidney organoids compared with non-transplanted organoids. Our laboratory also transplanted kidney organoids derived from hPSCs beneath the renal capsular space of nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mice. The transplanted kidney organoids vascularized with the host mouse and developed nephron-like structures ([Fig. 2](#f2-kjim-2018-198){ref-type="fig"}).

The therapeutic effectiveness of transplanting kidney organoids for kidney diseases has not yet been described but can be predicted based on previous reports \[[@b54-kjim-2018-198],[@b56-kjim-2018-198]\]. Toyohara et al. \[[@b56-kjim-2018-198]\] induced hPSCs into OSR1^+^SIX2^+^ renal progenitors, which were capable of reconstituting 3D proximal renal tubule-like structures *in vitro* and *in vivo*. They transplanted these human iPSC-derived renal progenitors cells into the kidney subcapsular space of mice in an ischemia/reperfusion injury AKI model, which resulted in suppression of the elevation of blood urea nitrogen and serum creatinine levels and attenuation of histopathological changes, such as tubular necrosis, tubule dilatation with casts, and interstitial fibrosis. Their data indicate that the renoprotective benefits originated from the trophic effects produced by the transplanted renal progenitor cells.

Another study was performed using a cisplatin injury-induced AKI mouse model \[[@b54-kjim-2018-198]\]. Imberti et al. \[[@b54-kjim-2018-198]\] induced renal progenitors from human iPSCs and infused them intravenously into mice with cisplatin-induced AKI. Injecting human iPSCs derived from renal progenitor cells restored renal function and structure in mice with cisplatin-induced AKI. Interestingly, different from Toyohara et al. \[[@b56-kjim-2018-198]\], these authors reported robust engraftment of human iPSCs derived from renal progenitor cells into damaged tubules of the host mouse kidney. Although it remains unclear whether renal recovery from AKI is due to the integrated human iPSCs derived from renal progenitor cells, or to regenerated tubular cells via paracrine effects arising from infused iPSC-derived renal progenitor cells, these data provide the basis for future applications of kidney organoids derived from hPSCs in regenerative therapy.

Recellularization of decellularized kidney scaffolds
----------------------------------------------------

Transplantation of a regenerated kidney using kidney scaffolds may be an attractive therapeutic option for patients with ESRD. Recellularization of decellularized kidney scaffolds with renal progenitor cells and endothelial cells is important for generating bioengineered kidneys for clinical use in the future, considering the successful clinical transplantation of recellularized tracheal scaffolds from decellularized cadaveric trachea \[[@b58-kjim-2018-198],[@b59-kjim-2018-198]\].

One group performed experimental orthotopic transplantation of re-populating decellularized kidneys \[[@b60-kjim-2018-198]\]. They seeded decellularized rat kidney scaffolds with rat neonatal kidney cells via the ureter and human umbilical vascular endothelial cells via the renal artery, and then perfused it in a whole-organ bioreactor. The decellularized rat kidney scaffolds were successfully recellularized. The repopulated kidneys produced rudimentary urine *in vitro*. Furthermore, when these bioengineered kidneys were transplanted in an orthotopic position in rats, the grafts were perfused by the recipient's circulation and produced urine through the ureteral conduit *in vivo* \[[@b60-kjim-2018-198]\].

Achieving an appropriate combination of cell types is one of the main issues in recellularization of decellularized kidney scaffolds. Thus, various combinations of cell types, such as renal cells with endothelial cells, including mouse ESCs \[[@b61-kjim-2018-198],[@b62-kjim-2018-198]\], human iPSC-derived endothelial cells with human renal cortical tubular epithelial cells \[[@b63-kjim-2018-198]\], rat aorta endothelial cells with rat epithelial tubular cells \[[@b64-kjim-2018-198]\], and human umbilical vascular endothelial cells with rat neonatal kidney cells \[[@b60-kjim-2018-198]\] have been explored.

Recellularization with renal progenitor cells and endothelial cells derived from human iPSCs results in abundant repopulation of decellularized kidney scaffolds and formation of a vascular network \[[@b65-kjim-2018-198]\]. Du et al. \[[@b65-kjim-2018-198]\] generated PAX2^+^ renal progenitor cells and endothelial cells from human iPSCs, which repopulated decellularized kidney scaffolds. Interestingly, the expression levels of genes related to renal development were higher in the recellularized group that had PAX2^+^ renal progenitor cells and endothelial cells than in the group that only had PAX2^+^ renal progenitor cells. When the recellularized kidney scaffolds were implanted in immunodeficient mice, glomerular assembly and function were achieved by recellularization with renal progenitor cells and endothelial cells. That study provided evidence for the vital role of endothelial cells in the generation of a functional whole kidney from a kidney scaffold, and highlighted the usefulness of iPSC-derived nephrogenic progenitors.

Numerous obstacles must be overcome to clinically apply bioengineered kidneys: optimization of cell-seeding protocols to create human-sized scaffolds, upscaling of biomimetic organ cultures, and differentiation and expansion of the required cell types from clinically feasible sources \[[@b60-kjim-2018-198]\]. Pigs may be suitable for decellularized kidney scaffolds because of the similarity in size and microarchitecture between pig and human kidneys \[[@b66-kjim-2018-198]\]. To achieve repopulation with a broader variety of different kidney-like cell types and appropriate organization, kidney organoids derived from hPSCs may be suitable cell sources for recellularization. However, whether kidney organoids derived from iPSCs can be used as cell sources to seed decellularized kidney scaffolds has not been evaluated.

OBSTACLES
=========

Despite biotechnological advances, applications of kidney organoids derived from human iPSCs have just begun and there are many obstacles to overcome for their clinical use. The safety of kidney organoids is an important concern for clinical use. Human iPSCs can form tumors. Some populations of progenitor cells in kidney organoids derived from iPSCs are not fully differentiated. Thus, regenerative therapy using kidney organoids may not be free from the risk of tumor development. Fortunately, no study thus far has reported the development of tumors in patients treated with hPSCs \[[@b67-kjim-2018-198]\]. Quality control of iPSCs to ensure that they have a normal karyotype is also required \[[@b67-kjim-2018-198]\].

Five different protocols have been published to differentiate kidney organoids from hPSCs \[[@b1-kjim-2018-198]-[@b4-kjim-2018-198]\]. The phenotypic characteristics of kidney organoids vary according to the differentiation protocol \[[@b47-kjim-2018-198],[@b68-kjim-2018-198]\]. No protocol generates kidney organoids that completely recapitulate the complex structural and functional nature of kidneys, which limits their efficacy for kidney disease modeling and regenerative therapies. More precise and standardized differentiation protocols are needed.

CONCLUSIONS
===========

Many people suffer from CKD \[[@b49-kjim-2018-198],[@b50-kjim-2018-198]\] and regenerative medicine may be a promising therapeutic option. Recent advances in differentiating kidney organoids from hPSCs and biotechnological advances have allowed for diverse applications of kidney organoids in the clinical setting. Precise modeling of genetic kidney diseases by CRISPR genome editing and advanced high-throughput technologies is a powerful tool for drug screening and developing new therapies. Further development of the "kidney on a chip," based on kidney organoids and 3D-bioprinting techniques, will hopefully allow for nephrotoxicity evaluations with accuracy similar to that *in vivo*. Regenerative therapy using kidney organoids might be a game changer in the battle against kidney diseases. Despite the challenges that need to be overcome for clinical application of kidney organoids, kidney organoids derived from hPSCs appear to have great potential.
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![Schematic presentation of the clinical application of kidney organoids derived from human pluripotent stem cells. CRISPR, clustered regularly interspaced short palindromic repeat.](kjim-2018-198f1){#f1-kjim-2018-198}

![Representative images immunohistochemical staining images (with human nuclear antibody \[HNA\]) after transplantation of kidney organoids derived from human pluripotent stem cells (hPSCs) into kidney of nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mouse. Scale bars, 0.1 mm. Transplanted kidney organoids derived from hPSCs grew with nephron-like structures and the cells in transplanted kidney organoids predominantly originated from the human inducible pluripotent stem cells. Black arrowheads indicate the glomerulus-like structure and white arrowheads indicate the tubule-like structure in transplanted graft.](kjim-2018-198f2){#f2-kjim-2018-198}
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Approaches for drug screening and nephrotoxicity testing

                  Renal tubular cells-based approaches                                                         hPSCs-based approaches                                                                     Kidney organoids-based approaches                                                                                                                                                                                                                                              
  --------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  Cell sources    MDCK cells, LLC-PK1 cells, HK-2 cells                                                        Primary human RPTECs                                                                                                                                                                                                                                                                                                                                                      
  Advantages      Established stable cell lines with renal transporters                                        Express transepithelial transporters and metabolic enzymes, relatively high predictivity   Differentiate to PT-like cells           Differentiate to PT-like cells, relatively high predictivity        Contains diverse renal cells including proximal and distal tubular cells, endothelial cells, podocyte and nephrogenic cells, available highthroughput screening   
  Disadvantages   Donor species differences, relatively low predictivity, limited transporters in HK-2 cells   Lose their PT characteristics during prolonged cultivation, donor-to-donor variability     Not free from ethical and legal issues   Unable to mimic the diverse renal cells, ECM, and vascularization   Not free from ethical and legal issues                                                                                                                            Immaturity, maldifferentiation to non-renal cells

hPSC, human pluripotent stem cell; ESC, embryonic stem cell; iPSC, inducible pluripotent stem cell; MDCK, Madin-Darby canine kidney; LLC-PK1, proximal-like porcine kidney 1; HK-2, human kidney 2; RPTEC, renal proximal tubular epithelial cell; PT, proximal tubule; ECM, extracellular matrix.
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